🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 4 of 55

  1. ATEZOLIZUMAB, COBIMETINIB, VEMURAFENIB

    Fondazione Telethon ETS

    high-risk, surgically resectable BRAF mutated and wild-type Melanoma

    phase 2 small molecule active

    1 trial

  2. ATRN-119

    Aprea Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  3. ATRN-119

    Aprea Therapeutics

    HPV Positive Oropharyngeal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  4. AU-011

    Aura Biosciences

    Uveal Melanoma

    phase 2 small molecule completed

    1 trial

  5. AU-011

    Aura Biosciences

    Eye Cancer

    phase 2 small molecule active

    1 trial

  6. AUR103 Calcium

    Disc Medicine

    HER 2 Positive Gastric Cancer

    phase 2 small molecule terminated

    1 trial

  7. AUTO1

    Autolus GmbH

    Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

    phase 2 mab active

    2 trials

  8. AUTO3

    Autolus GmbH

    Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 mab terminated

    1 trial

  9. AUTO3 (CD19/22 CAR T cells

    Autolus GmbH

    B Acute Lymphoblastic Leukemia

    phase 2 mab completed

    1 trial

  10. AUTO4

    Autolus GmbH

    T Cell Non-Hodgkin Lymphoma

    phase 2 mab terminated

    1 trial

  11. AUTOLOGOUS DENDRITIC CELLS LOADED WITH AUTOLOGOUS TUMOR LYSATE, Tecentriq 1 200 mg concentrate for solution for infusion

    The George Institute

    Lung Cancer

    phase 2 small molecule active

    1 trial

  12. AUY922

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastrointestinal Stromal Tumor

    phase 2 small molecule active

    1 trial

  13. AUY922

    Novartis Pharmaceuticals

    Advanced HER2-positive Breast Cancer

    phase 2 small molecule completed

    1 trial

  14. AVELUMAB, Erbitux 5 mg/mL solution for infusion

    Fondazione Telethon ETS

    recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  15. AVN944

    Vertex Pharmaceuticals (Australia) Pty.

    Pancreatic Cancer

    phase 2 small molecule terminated

    1 trial

  16. AZD0022, AZD0022, Erbitux 5 mg/mL solution for infusion

    AstraZeneca AB

    Non Small Cell Lung Cancer Colorectal Cancer Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  17. AZD0486, AZD0486

    AstraZeneca AB

    Relapsed or Refractory Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  18. AZD0516, AZD9574, AZD9574, AZD9574, AZD9574

    AstraZeneca AB

    Metastatic Prostate Cancer

    phase 2 small molecule active

    1 trial

  19. AZD0901, Rilvegostomig, DS-8201a

    AstraZeneca AB

    Locally Advanced Resectable Gastroesophageal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  20. AZD2014

    Samsung Bioepis NL B.V.

    Cancer of Stomach

    phase 2 small molecule terminated

    1 trial

  21. AZD2265 (FPI-2265)

    AstraZeneca

    Metastatic Prostate Cancer

    phase 2 small molecule active

    1 trial

  22. AZD2281

    AstraZeneca

    Ovarian Neoplasms

    phase 2 small molecule completed

    1 trial

  23. AZD4360

    AstraZeneca AB

    Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  24. AZD4512

    AstraZeneca AB

    Non-Hodgkin lymphoma (NHL)

    phase 2 small molecule active

    1 trial

  25. AZD4512

    AstraZeneca AB

    B-cell acute lymphoblastic leukemia (B-ALL)

    phase 2 small molecule active

    1 trial

  26. AZD5069

    United Therapeutics Europe Ltd

    Metastatic Castration Resistant Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  27. AZD5363

    United Therapeutics Europe Ltd

    Adenocarcinoma of the Prostate

    phase 2 small molecule active

    1 trial

  28. AZD5363

    Cardiff Oncology

    Estrogen Receptor Positive Breast Cancer

    phase 2 small molecule active

    1 trial

  29. AZD5363 when combined with weekly paclitaxel.

    AstraZeneca

    Advanced or Metastatic Breast Cancer

    phase 2 small molecule completed

    1 trial

  30. AZD6738

    United Therapeutics Europe Ltd

    Breast Neoplasm

    phase 2 small molecule active

    1 trial

  31. AZD6738, Ceralasertib

    AstraZeneca AB

    Advanced Cancer Whose Tumours Contain Molecular Alterations

    phase 2 small molecule active

    1 trial

  32. AZD6738, Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets, Ceralasertib, AZD6738

    AstraZeneca AB

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  33. AZD7789

    AstraZeneca AB

    Advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma, Advanced or Metastatic Non-small Cell Lung Carcinoma, Advanced or Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  34. AZD8931

    AstraZeneca

    Neoplasms

    phase 2 small molecule terminated

    1 trial

  35. AZD8931

    United Therapeutics Europe Ltd

    Metastatic Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  36. AZD9291

    Samsung Bioepis NL B.V.

    Non-Small Cell Lung Cancer With EGFR T790M Mutation

    phase 2 small molecule active

    1 trial

  37. AZD9291

    Hospital Authority, Hong Kong

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  38. AZD9574, DS-8201a, TEMOZO-cell ®250 mg Hartkapseln, AZD9574, TEMOZO-cell® 140 mg Hartkapseln, TEMOZO-cell® 100 mg Hartkapseln, TEMOZO-cell® 20 mg Hartkapseln, AZD9574, TEMOZO-cell® 180 mg Hartkapseln, TEMOZO-cell® 5 mg Hartkapseln, AZD9574, Datopotamab deruxtecan

    AstraZeneca AB

    Module 1: advanced/relapsed ovarian, breast, pancreatic or prostate cancer where patients loss of function or predicted loss of function mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D, Module 4: advanced,unresectable and HER2+ metastatic solid tumours; NSCLC, HER2 activating mutation, Module 5: advanced,unresectable or metastatic solid tumours in breast, endometrial, ovarian and prostate cancer, Module 3: advanced/relapsed HER2-negative breast, ovarian, prostate, or pancreatic cancer and expressing BRCA1m, BRCA2m, PALB2m, RAD51Cm or RAD51Dm, IDH-mutant recurrent glioma, breast cancer (without BM), Module 2: IDH-mutant glioma

    phase 2 small molecule active

    1 trial

  39. AZD9750, Saruparib

    AstraZeneca AB

    Metastatic Prostate Cancer

    phase 2 small molecule active

    1 trial

  40. AZD9793

    AstraZeneca AB

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  41. AZITROMICINA ZENTIVA 500 mg compresse rivestite con film, Bassado 100 mg compresse, CEBION

    Sana Biotechnology

    Breast Cancer

    phase 2 small molecule active

    1 trial

  42. Abemaciclib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Metastases From Colorectal Cancer (mCRC)

    phase 2 small molecule active

    1 trial

  43. Abemaciclib

    Teva Pharma GmbH

    Triple Negative Breast Neoplasms

    phase 2 small molecule active

    1 trial

  44. Abemaciclib, TEMOZOLOMIDE , Verzenios 50 mg film-coated tablets, IRINOTECAN

    Eli Lilly Co.

    Relapsed/Refractory Solid Tumors

    phase 2 small molecule active

    1 trial

  45. Abevmy 25 mg/mL concentrate for solution for infusion., CAPECITABINE VIATRIS 150 mg, comprimé pelliculé, IRINOTECAN VIATRIS 20 mg/ml, solution à diluer pour perfusion, OXALIPLATINE ARROW LAB 5 mg/mL, solution à diluer pour perfusion, Fluorouracil 25 mg/ml Solution for Injection or Infusion, Erbitux 5 mg/mL solution for infusion, Vectibix 20 mg/ml concentrate for solution for infusion

    CERO THERAPEUTICS HOLDINGS, INC.

    Patients with newly diagnosed advanced peritoneal metastasis from colon and colorectal junction cancer

    phase 2 small molecule active

    1 trial

  46. Abexinostat

    Xynomic Pharmaceuticals

    Non Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  47. Abiraterone Acetate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  48. Abiraterone Acetate

    United Therapeutics Europe Ltd

    Metastatic Castration Resistant Prostate Cancer

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.